What is Growth Strategy and Future Prospects of Healthpeak Properties Company?

Following the 2024 combination with Physicians Realty Trust, the company runs a simplified two-engine model: life science and medical office, with selective senior housing exposure only where risk-adjusted returns are compelling. The combined enterprise benefits from an investment-grade-capacity balance sheet and a broader tenant roster that improves leasing velocity and cross-market relationships.

Life science expansion concentrates on Boston/Cambridge, South San Francisco, and San Diego to capture NIH- and pharma-funded research spillovers; medical office growth targets system-affiliated outpatient nodes in Sun Belt and high-growth suburbs adjacent to major hospitals.

A multi-year development pipeline in the low-single billions of dollars targets stabilized yields near mid-6% for labs and mid-5% for top-tier medical office, with phased deliveries aligned to leasing progress and market funding normalization.

A sell-to-grow program monetizes non-core assets with targeted annual dispositions in the hundreds of millions to fund higher-yield development and accretive tuck-ins while keeping leverage within management guardrails; management remains open to campus-adjacent acquisitions to densify nodes and realize synergies.

Post-merger guidance targets balanced growth from same-store NOI and development deliveries. Management expects medical office same-store NOI to track in the low-2% range in a normalized environment, while life science same-store NOI should trend from flat to low-single-digit growth as leasing reaccelerates.

Annualized G&A synergies from the 2024 merger are expected in the tens of millions, largely realized within 12–18 months, underpinning FFO per share stabilization and modest growth; targeted development yields are mid-6% for labs and mid-5% for MOBs, supporting spread over WACC.

Investment-grade ratings in the BBB/Baa range support unsecured debt access; net debt/EBITDA sits around mid-5x with a glidepath to improve leverage via retained cash flow, JVs and asset recycling. An undrawn revolver in the billions provides liquidity for pipeline commitments without heavy equity issuance.

Priorities include funding pre-leased developments, selective accretive acquisitions around existing clusters, and maintaining a competitive dividend with an AFFO payout ratio aimed in the mid-60s to low-70s% over the cycle; non-core dispositions of hundreds of millions annually will be redeployed to higher-growth assets.

Changes to Medicare/Medicaid reimbursement, site-of-care incentives, or lab regulation can alter tenant economics; the REIT uses lease escalators, on-campus MOB preference, and scenario planning to buffer impacts.

Mitigation includes pursuing staggered expirations, collateral/security packages, and diversification across health systems and life-science tenants to reduce single-counterparty exposure.

Management targets mid-5x leverage, prioritizes capital recycling and paces starts to pre-leasing levels to support investment-grade ratings and maintain access to capital markets.

Use of phased projects, pre-leasing triggers, contingency budgets and partner JVs reduces single-project risk; monitoring shows development pipeline metrics and pre-lease rates as early warning indicators.